Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 1

Conditions

Ovarian Neoplasms 2Neuralgia 1Breast Neoplasms 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Telmisartan × Clear all
NCT06815497 2026-01-28

Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

Dartmouth-Hitchcock Medical Center

Phase 2 Recruiting
33 enrolled
Gynecologic

Ovarian Neoplasms

NCT05322889 2024-08-28

PrevTel

Fraunhofer Institute for Translational Medicine and Pharmacology ITMP

Phase 2 Completed
35 enrolled
BreastGynecologic

Breast Neoplasms, Neuralgia, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡